europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio sat down with new member SenseUp, to find out about the natural evolution approach for novel protein and RNA products

13/12/2022
INTERVIEW
Georg Schaumann

About Georg Schaumann
Georg studied biology in Düsseldorf and Aachen, before inventing single-cell biosensors for microbial strain development by natural evolution for his PhD at Forschungszentrum Jülich. He started SenseUP as a spin-off project in 2015, and raised funding with Helmholtz-Enterprise, GO-Bio phase I & II accompanied by two seed-financing rounds. SenseUP GmbH began commercial activity in mid 2017 and today has an active team of 12 and has received awards from German, European and global institutions. Georg is a father of two and lives in Cologne.

Interview with Dr. Georg Schaumann, CEO and Founder at SenseUP

1) What inspired the foundation of SenseUp?

SenseUP was founded by scientists with the desire to translate great scientific achievements into real-world applications. We believe that science and technology will strongly contribute to solving the world’s biggest problems. But to do so, they must be  implemented in industrial applications and that’s what SenseUP was founded for and is delivering on now.

2) What are the policy areas which offer opportunities and potential challenges for SenseUp?

Opportunities: Bio-technologies such as ours will enable the transition of many industrial sectors away from an oil, chemical or animal base to new solutions that better support environmental goals and a growing population. Policies that support environmental and climate regulation can accelerate this transition.

Challenges: In Europe, the regulatory process for novelty products is extremely long and complex. We need this to change to avoid innovation migrating to more accommodating parts of the world.

3) What are your plans for growth?

Since 2019, SenseUP has been working on an RNA program to explore and identify novel applications with strong commercial value. We have now started developing a range of RNA products based on microbial fermentation using SenseUp’s patented Corynebacterium and natural evolution technology.

Our aim is to develop sustainable and effective commercial products that are ready for industrial-scale production at low cost and can be launched in the years to come in cooperation with strategic industrial partners.

4) How do you see SenseUp being able to transform the biotech industry?

By delivering on our vision! This is: “Enabling a healthy and sustainable future by unlocking the path to valuable proteins and RNA”

RNA has revolutionary potential as a therapeutic agent for both human and animal health, as well as for use as a biopesticide in agriculture.

We are targeting animal parasites and plant pathogens that cause financial losses worth billions of Euros, in addition to positive impact on human, animal and environmental health.

Website Size Members PR (1)

Interview with SenseUp


Download
2022_12_G_O_Interview-with-New-Member-SenseUpDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more
19/12/2022

The Association of Biotechnological Companies Bioforum joins EuropaBio: representing Polish biotech at European legislative fora and involving Polish companies in the debate about the future of the industry


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies